Company: AZN
Filing Date: 2025-04-29
Form Type: 6-K
Source: 0001654954-25-004745
Chunk: 5

Company: ASTRAZENECA PLC
Filing Date: 2025-04-29
Form: 6-K
Chunk 5
---
 Metrics and Evaluation (IHME) in Seattle, United States, in 2024. Accessed April 2025.

5. American Cancer Society. Signs and Symptoms of Chronic Lymphocytic Leukemia. Available at: https://www.cancer.org/cancer/types/chronic-lymphocytic-leukemia/detection-diagnosis-staging/signs-symptoms.html . Accessed April 2025.

6. National Cancer Institute. Chronic lymphocytic leukemia treatment (PDQ ® )-Patient version. Available at: https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq . Accessed April 2025.

7. ClinicalTrials.gov. Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY). Available at: https://clinicaltrials.gov/study/NCT03836261 . Accessed April 2025.

8. Dube S, et al. Continued Increased Risk of COVID-19 Hospitalisation and Death in Immunocompromised Individuals Despite Receipt of ≥4 Vaccine Doses: Updated 2023 Results from INFORM, a Retrospective Health Database Study in England. Poster P0409 at ECCMID 2024.

9. Wu J, et al. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol . 2016;9(21).

#### Adrian Kemp

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date: 29 April 2025

| By: /s/           
 Adrian Kemp       |
| Name:             
 Adrian Kemp       |
| Title:            
 Company Secretary |